Eli Lilly and Company

Equities

LLY

US5324571083

Pharmaceuticals

Market Closed - Nyse 18:00:02 29/11/2024 GMT 5-day change 1st Jan Change
795.35 USD +0.91% Intraday chart for Eli Lilly and Company +6.33% +36.44%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
S&P 500 Posts Weekly Rise to Fresh Record, Ends November With Strongest Monthly Gain of Year 11-29 MT
Eli Lilly's Flortaucipir Approved by UK Regulator to Test for Alzheimer's Disease 11-27 MT
Amgen's Obesity Candidate MariTide Must Mitigate Tolerability Issues to Compete with Blockbuster Tirzepatide, Truist Says 11-27 MT
Eli Lilly Wins UK Approval for Alzheimer's Disease Diagnostic Agent 11-27 MT
Eli Lilly Wins UK Approval for Alzheimer's Disease Diagnostic Agent 11-27 MT
Health Care Up as Ely Lilly Rallies on Medicare Proposal -- Health Care Roundup 11-26 DJ
Sector Update: Health Care Stocks Advance Tuesday Afternoon 11-26 MT
Top Midday Stories: Automaker Shares Fall on New Trump Tariff Threat; Amgen Shares Tumble on Obesity Drug Study Results 11-26 MT
Novo Nordisk, Eli Lilly shares up as Biden proposes obesity coverage 11-26 RE
Sector Update: Health Care Stocks Mixed Premarket Tuesday 11-26 MT
Eli Lilly, Nordisk Shares up Pre-Bell on White House Proposal to Expand Medicaid, Medicare Coverage of Weight-Loss Drugs 11-26 MT
Novo Nordisk shares rise as Biden proposes obesity care coverage 11-26 RE
Eli Lilly, Novo Nordisk Press Employers to Cover the Cost of Weight-Loss Drugs 11-26 MT
North American Morning Briefing : Stock Futures -2- 11-26 DJ
White House Proposes Expanding Medicare, Medicaid Coverage for Anti-Obesity Drugs 11-26 MT
Biden Administration Proposes Medicare, Medicaid Coverage of Weight-Loss Drugs 11-26 MT
Cassana Sciences collapsed after study disappointment in Alzheimer's 11-26 FW
Drug Compounders Fight Drugmaker Efforts to Push Them Out of Market for GLP-1 Medications 11-25 MT
Lexaria Bioscience Corp.'s GLP-1 Human Pilot Study #3 Completes Dosing as Scheduled 11-25 CI
Sanofi plans to change hospital drug-discount program, WSJ reports 11-22 RE
Hims & Hers Health Shares Rise Thursday Amid Extension of FDA Decision 11-22 MT
Wall Street awaits Amgen weight-loss drug data expected to move shares 11-21 RE
Health Care Climbs as Obesity-Drug Makers Rebound - Health Care Roundup 11-20 DJ
China-based biotech Laekna teams up with Lilly to develop muscle preserving obesity drug 11-20 RE
Laekna, Inc. Announces a Clinical Collaboration with Eli Lilly and Company to Develop LAE102 11-20 CI
Chart Eli Lilly and Company
LLY: Dynamic Chart
Logo Eli Lilly and Company
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems; - oncology (19.5%); - immunology diseases (11.1%); - neurology (8.4%): primarily drugs used in treating depression and schizophrenia; - other (3.3%). Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Employees
43,000
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
surperformance-ratings-light-chart ELI-LILLY-AND-COMPANYMore Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
795.35USD
Average target price
992.18USD
Spread / Average Target
+24.75%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. LLY Stock
  4. News Eli Lilly and Company
  5. JPMorgan Adjusts Price Target on Eli Lilly and Co. to $1,000 From $900, Maintains Overweight Rating
LAST HOURS | BLACK FRIDAY -40%: Unlock Tomorrow's Top Investments with Our Exclusive Subscriber-Only Tools!
d
:
:
BENEFIT NOW